Stocks / PFE

PFE stock forecast

PFIZER INC · Healthcare · Drug Manufacturers - General

The model's rating

Greatly Outperform

PFE is rated Greatly Outperform as of September 29, 2026: its medium-term return forecast is in the top fifth of the stocks the model scores.

Create a free account to compare any two stocks; the numeric score is part of Premium.

PFE is not among the 20 largest holdings published for 2026 Q4. See the portfolio

PFE against the S&P 500

PeriodPFES&P 500 (SPY)
1 month+0.2%-0.3%
3 months+21.5%+2.5%
Year to date+20.5%+12.7%
1 year+19.8%+15.7%

Total return, dividends included.

Key numbers

Price$28.52
Market cap162.55 Billion
P/E (trailing 12 months)37.5
P/S (trailing 12 months)2.5
P/B (latest quarter)1.7
Gross margin73.2%
Net profit margin6.8%
Return on equity4.9%
Beta0.3

As of August 4, 2026.

PFE and its closest peers

StockCompanyMarket capModel rating
GILD GILEAD SCIENCES INC 184.82 Billion Outperform GILD vs PFE
BMY BRISTOL MYERS SQUIBB CO 127.47 Billion Outperform PFE vs BMY
AMGN AMGEN INC 227.88 Billion Outperform AMGN vs PFE
BIIB BIOGEN INC 33.37 Billion Outperform PFE vs BIIB
MRK MERCK & CO INC 358.5 Billion Greatly Outperform
ABBV ABBVIE INC 462.26 Billion Outperform
Hear when the model's rating on PFE changes
One email on Tuesdays, and the new quarter's picks the day they publish. Unsubscribe in one click.

Questions

What does the Upfront Investment model say about PFE?

The model rates PFIZER INC (PFE) "Greatly Outperform" as of September 29, 2026, which means its medium-term return forecast is in the top fifth of the stocks the model scores. The rating is a statistical forecast, not a recommendation to buy or sell.

How is the PFE rating produced?

A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.

Is PFE in the Upfront Investment model portfolio?

PFE is not among the 20 largest holdings published for 2026 Q4.

The rating is the output of a statistical model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.